A Phase 3 interventional study of Remibrutinib and Placebo in Chronic Inducible Urticaria, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 130 sites in 28 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 3, parallel group, placebo-controlled, double-blind, confirmatory study in patients with CINDU, with an optional Open-label Extension (OLE).
The purpose of the core period (52 weeks of treatment) of this study is to evaluate the efficacy, safety, and tolerability of remibrutinib (LOU064) vs. placebo in adults suffering from CINDU inadequately controlled by H1-antihistamines (H1-AHs).
The purpose of the OLE period is to collect long-term efficacy, safety, and tolerability data on remibrutinib in participants after having completed the Core period
This study consists of a core and extension periods.
The Core period (6 arms) has a total duration of up to 60 weeks including a double-blind placebo-controlled treatment period until Week 24 followed by open-label treatment with remibrutinib up to Week 52. The primary endpoint for all CINDU subtypes is assessed at Week 12.
The Core period consists of:
The duration of the Open-label Extension period will be approximately 3 years where participants can switch from observation to treatment depending on if they start developing symptoms. Only those participants participating in the Open-label Extension Treatment period will receive remibrutinib. The participants in the Open-label Extension Observation period will not receive remibrutinib
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria for core period:
The following response to the provocation test for each subtype is required at the randomization visit :
Inclusion criteria for the OLE:
Participants who have completed the Core period up to Week 52 and are willing to enter the OLE period
Exclusion Criteria for core period:
There are no exclusion criteria for OLE
Remibrutinib oral twice daily in participants with symptomatic dermographism
Drug: Remibrutinib
Placebo oral twice daily, symptomatic dermographism
Other: Placebo
Remibrutinib oral twice daily, cold urticaria
Drug: Remibrutinib
Placebo oral twice daily, cold urticaria
Other: Placebo
Remibrutinib oral twice daily, cholinergic urticaria
Drug: Remibrutinib
Placebo oral twice daily, cholinergic urticaria
Other: Placebo
Remibrutinib treated groups and arms
Placebo treated groups and arms
Proportion of participants with complete response in Total Fric Score; symptomatic dermographism
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Time frame: Week 12
Proportion of participants with complete response in critical temperature threshold; cold urticaria
The Temptest is used to induce itch and hives in participants with cold urticaria. Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Time frame: Week 12
Proportion of participants with itch numerical rating scale =0; cholinergic urticaria
Itch numerical rating scale, a scale from 0 to 10 Patients are asked to rate itching severity based on the worst level of itching in the past 24 h using an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable")
Time frame: Week 12
Change from baseline in Total Fric score; symptomatic dermographism
Total Fric score, a scale from 0-4 where a positive response with all four pins is TFS=4, while a positive only 1 pin - the largest pin is TFS=1
Time frame: Week 12
Change from baseline in criticial temperature threshold following Temptest; cold urticaria
Critical temperature threshold, as measured by the Temptest, determines the highest temperature that induces symptoms
Time frame: Week 12
Change from baseline in itch numerical rating scale; cholinergic urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 12
proportion of participants with Physician Global Assessment (PGA) severity of hives =0; cholinergic urticaria
Physician global assessment of severity of hives. This assessment is scored 0 to 4 with 0=no hives, 1=mild hives, 2=moderate hives, 3=severe hives and 4=very severe hives
Time frame: Week 12
Proportion of participants with complete response in TFS; symptomatic dermographism
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Time frame: Week 24
Proportion of participants with complete response in Critical Temperature threshold; cold urticaria
Critical Temperature Threshold, as measured by the Temptest, is the highest temperature that induces symptoms
Time frame: Week 24
Proportion of participants with complete response in itch numerical rating scale; cholinergic urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 24
Change from baseline in itch numerical rating scale in participants with symptomatic dermographism
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 12
Change from baseline in itch numerical rating scale in participants with cold urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 12
Proportion of participants with complete response in Total Fric score; symptomatic dermographism
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Time frame: Week 2
Proportion of participants with complete response in Critical Temperature Threshold; cold urticaria
Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Time frame: Week 2
Proportion of participants with itch NRS=0; cholinergic urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 2
Change from baseline in TFS in participants with symptomatic dermographism
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Time frame: Week 2
Change from baseline in Critical Temperature Threshold in participants with cold urticaria
Critical temperature threshold (CTT), as measured by the Temptest, determines the highest temperature that induces symptoms.
Time frame: Week 2
Change from baseline in itch NRS in participants with cholinergic urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 2
Change from baseline in itch NRS in participants with symptomatic dermographism
Total Fric score (a scale from 0-4 where a positive response with all of the four pins is TFS = 4, while a positive response with only one pin - the largest pin is TFS = 1)
Time frame: Week 2
Change from baseline in itch NRS in participants with cold urticaria
Itch numerical rating scale (NRS), scale from 0 to 10. 0 ("no itch") to 10 ("worst imaginable itch").
Time frame: Week 2
Proportion of participants with cholinergic urticaria with PGA=0
Physician global assessment of severity of hives is a 4-point scale (0 = no active disease, 1 = mild disease, 2 = moderate disease, 3 = severe disease).
Time frame: Week 2
Change from baseline in weekly most bothersome symptom NRS score on the USDD
Urtricara symptom daily diary (USDD). This daily diary records if the participant experiences any symptoms or avoided the triggers
Time frame: Week 12
Proportion of participants with DLQI=0-1
The Dermatology Life Quality Index (DLQI) is a 10-item dermatology-specific quality of life (QoL) measure. Subjects rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease-related QoL). A DLQI score of 0 or 1 means that there is no impact of a skin disease on the patient's life.
Time frame: Week 12
Occurrence of treatment emergent adverse events and serious adverse events during the study
Treatment emergent adverse events and serious adverse events are those that occur at any time only after treatment has started
Time frame: Week 52
Showing the first 100 of 130 sites across 28 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Ran from Dec 2023 to primary completion in May 2026, 29 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Remibrutinib
Chronic Inducible Urticaria